July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Clinical course and characteristics of uveitis associated with metastatic melanoma chemotherapy with Ipilimumab and Nivolumab
Author Affiliations & Notes
  • Goncalo A C Almeida
    Eye Ear and Mouth Unit, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom
  • Richard Bernhardt
    Eye Ear and Mouth Unit, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom
  • Ciara O'Hanlon Brown
    Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom
  • Footnotes
    Commercial Relationships   Goncalo Almeida, None; Richard Bernhardt, None; Ciara O'Hanlon Brown, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4210. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Goncalo A C Almeida, Richard Bernhardt, Ciara O'Hanlon Brown; Clinical course and characteristics of uveitis associated with metastatic melanoma chemotherapy with Ipilimumab and Nivolumab. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4210.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ipilimumab and Nivolumab are promising treatments for patients with metastatic melanoma. However their multiple side-effects, have been reported. Published data incidence reports uveitis as affecting 4-12% of patients treated.

We performed a retrospective observational clinical study of our treated patients in Kent Oncology Centre and Eye Unit. Our hypothesis was that the incidence and severity of uveitis was understated.

Methods : We analyzed our existing treated metastatic melanoma base for presence of uveitis from 2014-2017. In patients where uveitis was detected, the clinical characteristics, management and clinical course were collected and described for interpretation.

Results : 20 patients were treated in the period described. Of these 4 (20%) developed uveitis seen in our Eye Unit. All had bilateral involvement. 3 patients developed posterior uveitis, with specific phenotypes, 1 with a VKH-like illness and exudative detachments, 1 with severe bilateral panuveitis with choroidal granulomas, 1 developed depigmentation of the fundus involving the macula. 1 presented with anterior uveitis.

All eyes with posterior uveitis had vision loss at presentation. This improved on all with systhemic immunosuppression with steroids, with areas of permanent depigmentation present. The patient with depigmentation phenotype required additional immunomodulation with azathioprine, which halted progression. The patient with anterior uveitis was managed with topical steroids, with good result. All patients with posterior uveitis halted further chemotherapy.

Conclusions : Our single-centre results were collected retrospectively and present limitations pertaining to the small sample size and type of study. However, the incidence of uveitis seems higher on our centre (20%) relative to the published results. In addition the severity of the ocular inflammation is worse than the initial studies reporting on metastatic melanoma. In the author’s opinion this is new information, and should be further researched prospectively

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×